drugset / Trial / NCT01343368
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Phase 2
Terminated
19 enrolled
Masonic Cancer Center, University of Minnesota
Minnesota Medical Foundation · collab
Non-randomizedParallel-groupOpen-labelSupportive care
Summary
Women undergoing myeloablative allogeneic hematopoietic cell transplant (MA HCT) will receive GnRH agonist leuprolide. Women undergoing reduced intensity allogeneic (RIC) HCT will be observed.
Timeline
- Start
- 2011-07
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leuprolide | Other / unclassified | 0.2 mg | Intramuscular |
| Subject | Leuprolide | Other / unclassified | 11.25 mg | Intramuscular |